The precision of magnetic resonance imaging (MRI) measurement has improved over the years, and now scans can identify brain damage before symptoms begin showing. Whether the presence of new or expanding lesions predict disease progression is, however, still controversial, and clinicians have no guidance when making treatment decisions about the…
interferon-beta
Blood biomarkers in individual multiple sclerosis patients may help clinicians determine which treatments would be of most benefit to that person, according to researchers at Oklahoma Medical Research Foundation (OMRF). The study, published in the journal Neurology, Neuroimmunology & Neuroinflammation, is titled “Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.”…
EMD Serono, the subsidiary of Merck KGaA in the United States, recently announced that it will present new data on Rebif®, an interferon beta-1a therapy for relapsing-remitting multiple sclerosis (RRMS), at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be…
A study recently published in the journal PLoS One compared the use of a specific treatment based on interferon beta-1a with other approved injectable therapies in patients with relapsing-remitting multiple sclerosis (RRMS). The study is entitled “A Network Meta-Analysis of Efficacy and Evaluation of…
A team led by researchers at San Raffaele Scientific Institute in Italy and Brigham and Women’s Hospital in Boston, Massachusetts recently revealed a new genetic variant linked to multiple sclerosis (MS). The study is entitled “A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity” and is published in…
Researchers at the IRCCS Centro Neurolesi “Bonino-Pulejo” and the University of Messina in Italy have performed a review on the immunomodulatory activity reported for statins in the treatment of multiple sclerosis (MS) and on clinical trial results. The study was published in the journal Pharmacological…